This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 16:36, 18 February 2011 (Undid revision 414497995 by Jasonwithey (talk) - drugbox or chembox, but not both please). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:36, 18 February 2011 by Edgar181 (talk | contribs) (Undid revision 414497995 by Jasonwithey (talk) - drugbox or chembox, but not both please)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | High |
| Metabolism | Hepatic |
| Elimination half-life | 12 hours |
| Excretion | Renal and fecal |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.153.448  |
| Chemical and physical data | |
| Formula | C12H12N4O3 |
| Molar mass | 260.249 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Benznidazole (INN, formerly marketed by Hoffman-La Roche under the trade names Rochagan and Radanil) is an antiparasitic medication used in the treatment of Chagas disease. Its mechanism of action is difficult to find but it acts on microtubules. Roche donated the technology and rights to produce benznidazole to the Brazilian government.
Side effects
The side effects most commonly associated with benznidazole therapy are rash and gastrointestinal symptoms such as nausea. Rarely, peripheral neuropathy may present after prolonged treatment.
External links
- Template:Pt icon "Rochagan " (PDF). Hoffmann-La Roche. Retrieved 2006-11-27.
References
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |